ALK TKI Side Effects and Acquired Resistance - 2022 Program: Targeted Therapies Forum

Advanced ALK+, RET+ and MET+ NSCLC - 2022 Program: Targeted Therapies Forum - EnglishПодробнее

Mechanisms of ALK Resistance & Implications for TreatmentПодробнее

ROS1 ALK Initial Treatment, Acquired Resistance with Melina Marmarelis, MD and Charu Aggarwal, MDПодробнее

Full Video OnDemand -Targeted Therapies Patient Forum 2022 - for those living with Lung CancerПодробнее

Targeted Therapy Resistance Mechanisms in ALK+ NSCLCПодробнее

Side Effects of ALK-TKIs - 2022 Program: Targeted Therapies ForumПодробнее

ALK+ NSCLC Treatment Options - 2022 Program: Targeted Therapies ForumПодробнее

Emerging Therapies in ALK+ NSCLC - 2022 Program: Targeted Therapies ForumПодробнее

Life After 1st Line Targeted Therapy: What Next?Подробнее

ALK Inhibitors for Acquired Resistance: Zykadia and AlectinibПодробнее

Updates and unmet needs in ALK-mutated lung cancerПодробнее

2020 TTF EGFR Breakout PIOTROWSKA Part 2 - Current Options Upon Acquired Resistance to OsimertinibПодробнее

What is Acquired Resistance to Targeted Therapy, and Why Does it Occur?Подробнее

2020 TTF ALK SESSION QA PANEL The Future of MEK InhibitorsПодробнее

Resistance to ALK TKIsПодробнее

ALK Positive Forum Next Generation InhibitorsПодробнее

What targeted therapies are used for people with the ALK mutation?Подробнее